Avantor (NYSE:AVTR) Price Target Raised to $31.00 at TD Cowen

Avantor (NYSE:AVTR) had its price target lifted by TD Cowen from $28.00 to $31.00 in a report published on Monday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other brokerages have also recently issued reports on AVTR. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Avantor from $23.00 to $25.00 and gave the company a hold rating in a research note on Thursday, April 18th. Citigroup downgraded Avantor from a buy rating to a neutral rating and decreased their price objective for the company from $30.00 to $23.00 in a report on Wednesday, July 10th. Evercore ISI cut their target price on Avantor from $28.00 to $27.00 and set an outperform rating for the company in a research report on Tuesday, July 2nd. Stifel Nicolaus increased their price objective on Avantor from $27.00 to $28.00 and gave the stock a buy rating in a research note on Monday. Finally, Robert W. Baird boosted their target price on shares of Avantor from $26.00 to $27.00 and gave the company an outperform rating in a research note on Monday. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $27.21.

Avantor Stock Performance

NYSE AVTR opened at $26.49 on Monday. The company’s fifty day moving average is $22.56 and its two-hundred day moving average is $23.76. The firm has a market capitalization of $18.01 billion, a price-to-earnings ratio of 67.92, a P/E/G ratio of 2.82 and a beta of 1.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. Avantor has a 52-week low of $16.63 and a 52-week high of $28.00.

Insider Buying and Selling

In other news, insider Christophe Couturier 10,000 shares of the business’s stock in a transaction dated Tuesday, July 30th. The was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Versant Capital Management Inc lifted its stake in Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after buying an additional 1,102 shares during the period. Fifth Third Bancorp increased its stake in shares of Avantor by 125.3% in the 4th quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after acquiring an additional 694 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt raised its position in shares of Avantor by 565.5% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after acquiring an additional 1,131 shares during the period. Blue Trust Inc. boosted its stake in Avantor by 1,830.3% during the 2nd quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock worth $31,000 after acquiring an additional 1,391 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new position in Avantor during the fourth quarter valued at approximately $42,000. 95.08% of the stock is currently owned by institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.